Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4YU2

Crystal structure of DYRK1A with harmine-derivatized AnnH-75 inhibitor

Summary for 4YU2
Entry DOI10.2210/pdb4yu2/pdb
DescriptorDual specificity tyrosine-phosphorylation-regulated kinase 1A, TETRAETHYLENE GLYCOL, (1-chloro-7-methoxy-9H-beta-carbolin-9-yl)acetonitrile, ... (5 entities in total)
Functional Keywordstransferase, dyrk1a, down syndrome, inhibitor, harmine, structural genomics, structural genomics consortium, sgc
Biological sourceHomo sapiens (Human)
Total number of polymer chains4
Total formula weight170379.88
Authors
Chaikuad, A.,Wurzlbauer, A.,Nowak, R.,von Delft, F.,Arrowsmith, C.H.,Edwards, A.M.,Bountra, C.,Bracher, F.,Knapp, S.,Structural Genomics Consortium (SGC) (deposition date: 2015-03-18, release date: 2015-03-25, Last modification date: 2024-01-10)
Primary citationWurzlbauer, A.,Ruben, K.,Gurdal, E.,Chaikuad, A.,Knapp, S.,Sippl, W.,Becker, W.,Bracher, F.
How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
Molecules, 25:-, 2020
Cited by
PubMed Abstract: The β-carboline alkaloid harmine is a potent DYRK1A inhibitor, but suffers from undesired potent inhibition of MAO-A, which strongly limits its application. We synthesized more than 60 analogues of harmine, either by direct modification of the alkaloid or by de novo synthesis of β-carboline and related scaffolds aimed at learning about structure-activity relationships for inhibition of both DYRK1A and MAO-A, with the ultimate goal of separating desired DYRK1A inhibition from undesired MAO-A inhibition. Based on evidence from published crystal structures of harmine bound to each of these enzymes, we performed systematic structure modifications of harmine yielding DYRK1A-selective inhibitors characterized by small polar substituents at N-9 (which preserve DYRK1A inhibition and eliminate MAO-A inhibition) and beneficial residues at C-1 (methyl or chlorine). The top compound remains a potent DYRK1A inhibitor, and it is devoid of MAO-A inhibition. Its binding mode to DYRK1A was elucidated by crystal structure analysis, and docking experiments provided additional insights for this attractive series of DYRK1A and MAO-A inhibitors.
PubMed: 33339338
DOI: 10.3390/molecules25245962
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.9 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon